Huadong’s Mefatinib Approved by NMPA for EGFR‑Driven NSCLC
Huadong Medicine (SHE: 000963) announced that its Class 1 innovative drug Mefatinib Tablets has received marketing...
Drug
Hengrui Launches Henagliflozin Triple‑Combination Metformin for Type 2 Diabetes
Hengrui Medicine (SHA: 600276, HKG: 1276) today announced the commercial launch of its first independently developed...
CSPC’s SYH2061 Injection Receives NMPA Clinical‑Trial Approval for IgA Nephropathy
CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its independently developed Class 1 chemical novel drug...
Boehringer Ingelheim’s Nerandomilast Approved by China NMPA for Idiopathic Pulmonary Fibrosis
Boehringer Ingelheim announced that its oral selective phosphodiesterase‑4B (PDE4B) inhibitor Nerandomilast (JASCAYD®) has received formal...
PADCEV Yields 60 % EFS Reduction in MIBC – Astellas‑Pfizer EV‑303 Study
Astellas (TSE: 4503) and Pfizer (NYSE: PFE) announced that their pivotal Phase III EV‑303 (KEYNOTE‑905) trial...
AbbVie’s SELECT‑SWITCH Study Confirms Upadacitinib Outperforms Adalimumab in RA
AbbVie (NYSE: ABBV) announced positive topline data from its Phase IIIb/IV head‑to‑head trial, SELECT‑SWITCH, comparing upadacitinib...
Harbour BioMed Reports Phase II Success of Porustobart in MSS mCRC
China‑based Harbour BioMed (HKG: 2142) announced positive results from its multicenter, open‑label Phase II trial (NCT 05167071)...
GFH375 Enters Phase Ib/II at Peking University: GenFleet Targets KRAS G12D
GenFleet Therapeutics (Shanghai) Inc. (HKG: 2595) today announced that the first patient has been enrolled...
BIREOCCILIB OUTPERFORMS TRADITIONAL CDK4/6 IN BRIGHT‑3: Xuanzhu Biopharma Announces Interim Phase III Results at ESMO 2025
Xuanzhu Biopharmaceutical Co., Ltd. (HKG: 2575) announced that the interim analysis of the Phase III BRIGHT‑3...
Sichuan Biokin Secures NMPA Approval for BL‑M24D1 ADC, Targeting Relapsed Hematologic and Solid Tumors
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced that the National Medical Products Administration (NMPA)...
Huadong Medicine Secures FDA Approval for DR10624, First‑In‑Class Trispecific Agonist for Severe Hypertriglyceridemia
Huadong Medicine (SHE: 000963) announced that the Investigational New Drug (IND) application for DR10624 Injection,...
AstraZeneca & Daiichi Sankyo Announce 11.2% pCR Gain with Enhertu in DESTINY‑Breast11 at ESMO 2025
AstraZeneca (AZ, NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) disclosed the Phase III DESTINY‑Breast11 results at...
Indetek Laboratory Secures NMPA Approval for IDT‑001 Gel, a Novel Film‑Forming Therapy for SSTIs
Indetek Laboratory announced that the National Medical Products Administration (NMPA) has formally accepted the New...
Fosun‑Henlius Announces 26.8‑Month Median OS for Hetronifly Plus Chemo in Advanced NSCLC
Fosun Pharma (SHA: 600196) subsidiary Shanghai Henlius Biotech, Inc. (HKG: 2696) unveiled the final Phase III...
Novartis Announces Five‑Year NATALEE Results for Kisqali in HR+/HER2‑ Early Breast Cancer
Novartis (NYSE: NVS) presented the five‑year interim analysis of its pivotal Phase III NATALEE study at...
Novo Nordisk Secures FDA Approval for Rybelsus to Reduce Cardiovascular Risk in Type 2 Diabetes
Novo Nordisk (NYSE: NVO) announced that the U.S. Food and Drug Administration (FDA) has granted...
Sino Biopharmaceutical Announces Breakthrough Phase III Results for Culmerciclib in HR+/HER2‑ Negative Breast Cancer
Sino Biopharmaceutical (HKG: 1177) today presented the interim analysis of its CULMINATE‑2 Phase III study at...
Sichuan Biokin Launches Phase III Trial of T‑Bren for HER2‑Mutant NSCLC
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) announced today the enrollment of the first patient...
Anhui Anke Announces HuA21 Success in HER2‑Positive Gastric Cancer
Anhui Anke Biotechnology (Group) Co., Ltd. today released interim results from its Phase Ib/II study of...
Novartis Announces First‑In‑Class Phase III Data for Lutetium‑177 Vipivotide Tetraxetan in PSMA‑Positive Metastatic Hormone‑Sensitive Prostate Cancer
Novartis (NYSE: NVS) today disclosed the first data from its Phase III PSMAddition trial of lutetium‑177...